Determination of EC95 of remifentanil for smooth emergence from sevoflurane anesthesia in patients undergoing trans-femoral cerebral angiography
- Conditions
- Diseases of the nervous system
- Registration Number
- KCT0002691
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
Adults undergoing TFCA because of cerebrovascular disease ( age from 20 to70 years )
ASA class I - III
patients who agree to the clinical trial and signs written informed consent
- Symptoms or signs of increased intracranial pressure
- uncontrolled hypertension
- preoperative administration of an antitussive agent
- patients with gastroesophageal reflux
- allergic history with use of remifentanil or contraindication for remifentanil
- patients with arrythmia or congestive heart failure (new York heart association heart failure grade 3,4)
- Acute or chronic respiratory disease or patients who require ventilator care after Trans-femoral cerebral angiography
(Bronchial asthma, chronic obstructive lung disease, upper respiratory infection within 2 weeks etc.)
- severe obesity (BMI > 35 kg/m2)
- severe obstructive sleep apnea
- anticipated difficult airway
- A person who does not recover consciousness 20 minutes after discontinuing sevoflurane administration
(Consider delayed emergence and exclude the patient from trial)
- Patients who are judged to be inadequate to participate in clinical trials at the discretion of the researcher
- Patients who do not agree to participate in the study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method prevention of cough
- Secondary Outcome Measures
Name Time Method Mean arterial pressure (MAP);heart rate (HR);respiratory rate (RR);ETCO2 level;BIS score;emergence time;respiratory rate;sedation grade;aldrete score;side effect (pain, nausea/vomiting, shivering);duration of PACU stay